RD213

RD213 is a next-generation tumor-infiltrating lymphocyte (TIL) cell therapy genetically engineered to secrete a bispecific T cell engager (BiTE). This BiTE targets a tumor-associated antigen expressed on both tumor cells and the surrounding stroma, with minimal expression in normal tissues. The dual-targeting strategy aims to enhance TIL penetration through stromal barriers and promote the recruitment of endogenous peripheral T cells, leading to deeper immune infiltration and synergistic tumor control. RD213 is manufactured using proprietary StemTexp® and StaViral® platforms, preserving a favorable memory phenotype without inducing excessive activation or exhaustion. It has demonstrated enhanced cytotoxicity and cytokine production in vitro and superior anti-tumor efficacy in vivo, positioning it as a novel therapeutic strategy for refractory solid tumors.